Therapy of Peripheral T Cell Lymphoma: Focus on Nodal Subtypes

Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis

(2019) Narendranath Epperla et al.   Journal of Hematology & Oncology

Randomized Phase III Study of Alisertib or Investigator’s Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma

(2019) Owen A. O’Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

(2019) Steven I. Park et al.   CANCER

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

(2019) Tayla B. Heavican et al.   BLOOD

Factors Impacting the Real World Use of Autologous Stem Cell Transplantation (ASCT) for Newly Diagnosed Peripheral T Cell Lymphoma (PTCL)

(2019) Deepa Jagadeesh et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients

(2019) Andrea Janikova et al.   ANNALS OF HEMATOLOGY

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

(2019) Stefan K. Barta et al.   Clinical Lymphoma Myeloma & Leukemia

Molecular heterogeneity in peripheral T-cell lymphoma, not otherwise specified revealed by comprehensive genetic profiling

(2019) Yosaku Watatani et al.   LEUKEMIA

Effect of leucovorin administration on mucositis and skin reactions in patients with peripheral T-cell lymphoma or cutaneous T-cell lymphoma treated with pralatrexate*

(2019) Francine M. Foss et al.   LEUKEMIA & LYMPHOMA

FIRST-LINE THERAPY OF T-CELL LYMPHOMA: ALLOGENEIC OR AUTOLOGOUS TRANSPLANTATION FOR CONSOLIDATION - FINAL RESULTS OF THE AATT STUDY

(2019) O. Tournilhac et al.   HEMATOLOGICAL ONCOLOGY

TIPIFARNIB IN RELAPSED OR REFRACTORY ANGIOIMMUNOBLASTIC T-CELL LYMPHOMA (AITL) AND CXCL12+ PERIPHERAL T-CELL LYMPHOMA (PTCL): PRELIMINARY RESULTS FROM A PHASE 2 STUDY

(2019) T. Witzig et al.   HEMATOLOGICAL ONCOLOGY

CLINICAL AND BIOLOGICAL EVALUATION OF THE NOVEL CD30/CD16A TETRAVALENT BISPECIFIC ANTIBODY (AFM13) IN RELAPSED OR REFRACTORY CD30-POSITIVE LYMPHOMA WITH CUTANEOUS PRESENTATION: A BIOMARKER PHASE IB/IIA STUDY (NCT03192202)

(2019) A. Sawas et al.   HEMATOLOGICAL ONCOLOGY

INVESTIGATING SAFETY AND PRELIMINARY EFFICACY OF AFM13 PLUS PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE

(2019) S.M. Ansell et al.   HEMATOLOGICAL ONCOLOGY

ORAL 5-AZACYTIDINE AND ROMIDEPSIN EXHIBIT MARKED ACTIVITY IN PATIENTS WITH PTCL: A MULTICENTER PHASE I STUDY

(2019) Owen A O'Connor et al.   BLOOD

Defining the signatures of peripheral T-cell lymphoma, with a targeted 20-markers gene expression profiling assay (RT-MLPA)

(2019) Fanny Drieux et al.   HAEMATOLOGICA

The impact of stem cell transplantation on the natural course of peripheral T-cell lymphoma: a real-world experience

(2018) Sarah Rohlfing et al.   ANNALS OF HEMATOLOGY

Allogeneic hematopoietic stem cell transplantation for T-cell lymphomas

(2018) Norbert Schmitz et al.   BLOOD

RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis

(2018) Jose R. Cortes et al.   CANCER CELL

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

(2018) Monica Bellei et al.   HAEMATOLOGICA

Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy

(2018) Lee Ratner et al.   NEW ENGLAND JOURNAL OF MEDICINE

The outcome of peripheral T-cell lymphoma patients failing first-line therapy: a report from the prospective, International T-Cell Project

(2018) Monica Bellei et al.   HAEMATOLOGICA

CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymphoma (CHEMO-T): a phase 2, multicentre, randomised, open-label trial

(2018) Mary Gleeson et al.   Lancet Haematology

Tolerability and response of the novel SYK/JAK inhibitor cerdulatinib in a phase 2a study in relapsed/refractory peripheral t cell lymphoma (PTCL).

(2018) Steven M. Horwitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma

(2018) François Lemonnier et al.   BLOOD

Clinical and immunological responses after CD30-specific chimeric antigen receptor–redirected lymphocytes

(2017) Carlos A. Ramos et al.   JOURNAL OF CLINICAL INVESTIGATION

International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

(2017) Matthew J. Maurer et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes

(2017) Maren Bieling et al.   Oncotarget

Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling

(2017) Ming Wang et al.   Oncotarget

Autologous stem cell transplantation in first complete remission may not extend progression-free survival in patients with peripheral T cell lymphomas

(2016) Clinton Yam et al.   AMERICAN JOURNAL OF HEMATOLOGY

A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas

(2016) S. J. Kim et al.   ANNALS OF ONCOLOGY

Genomic signatures in T-cell lymphoma: How can these improve precision in diagnosis and inform prognosis?

(2016) Javeed Iqbal et al.   BLOOD REVIEWS

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

(2016) Kenneth R. Carson et al.   CANCER

Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas

(2016) Pier Luigi Zinzani et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

(2016) Bo Jia et al.   Hematology

Racial Patterns of Peripheral T-Cell Lymphoma Incidence and Survival in the United States

(2016) Scott V. Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients

(2016) Cinzia Pellegrini et al.   Journal of Hematology & Oncology

Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial

(2016) Francine Foss et al.   Journal of Hematology & Oncology

First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation

(2016) M Wilhelm et al.   Blood Cancer Journal

The biology and management of systemic anaplastic large cell lymphoma

(2015) G. Hapgood et al.   BLOOD

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

(2015) Ranjana H. Advani et al.   BRITISH JOURNAL OF HAEMATOLOGY

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

(2015) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial

(2015) Daryl Tan et al.   Lancet Haematology

Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study

(2015) Jehan Dupuis et al.   Lancet Haematology

Peripheral T-cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy

(2014) J. S. Abramson et al.   ANNALS OF ONCOLOGY

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

(2014) S. M. Horwitz et al.   BLOOD

Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry

(2014) F. Ellin et al.   BLOOD

Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network

(2014) Alex F. Herrera et al.   CANCER

Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma

(2014) Ethan Toumishey et al.   CANCER

Molecular genetics of peripheral T-cell lymphomas

(2014) Pier Paolo Piccaluga et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Multicenter Phase II Study of Mogamulizumab (KW-0761), a Defucosylated Anti-CC Chemokine Receptor 4 Antibody, in Patients With Relapsed Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

(2014) Michinori Ogura et al.   JOURNAL OF CLINICAL ONCOLOGY

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies

(2014) Nancy L Bartlett et al.   Journal of Hematology & Oncology

Survival of Patients With Peripheral T-Cell Lymphoma After First Relapse or Progression: Spectrum of Disease and Rare Long-Term Survivors

(2013) Vivien Mak et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Profiling Improves Classification and Prognostication of Nodal Peripheral T-Cell Lymphomas: Results of a Phase III Diagnostic Accuracy Study

(2013) Pier Paolo Piccaluga et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib in combination with CHOP as first-line treatment for patients with stage III/IV peripheral T-cell lymphomas: A multicentre, single-arm, phase 2 trial

(2012) Seok Jin Kim et al.   EUROPEAN JOURNAL OF CANCER

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

(2012) Francesco d'Amore et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Prospective, Open-Label, Phase II Trial of Bendamustine in Refractory or Relapsed T-Cell Lymphomas: The BENTLY Trial

(2012) Gandhi Damaj et al.   JOURNAL OF CLINICAL ONCOLOGY

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

(2010) N. Schmitz et al.   BLOOD

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

(2008) S. Mercadal et al.   ANNALS OF ONCOLOGY